OCUL on Nasdaq

OCULAR THERAPEUTIX, INC

American pharmaceutical preparations company based in Dover.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Q32 Bio Inc., Contineum Therapeutics, Inc. or Semnur Pharmaceuticals, Inc., or pick any stock.

  • TickerOCUL on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersDover, United States
  • Incorporated inDE2
  • Business address14 Crosby Drive, 3Rd Floor, Bedford, Ma 017302
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-519.8%Operating margin3
-511.9%Net margin3
-18.5%Revenue growth, 20253
-40.6%Return on equity3
-$216.9MFree cash flow3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 100% of the revenue OCULAR THERAPEUTIX, INC broke down this way in fiscal 2025.

  1. Product$51.8M3100%down 18% from 2024
  2. Collaboration Revenue$128.0K30%down 51% from 2024
Products and services by year
Products and services202320242025
Product$57.9M$63.5M$51.8M
Collaboration Revenue$573.0K$262.0K$128.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue3¢$6.6M
  • Research and development97¢$197.1M

Out of $52.0M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$52.0M in 2025+1129% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $4.2M$4.2M20192020: $17.4M$17.4M2020+312%2021: $43.5M$43.5M2021+150%2022: $51.5M$51.5M2022+18%2023: $58.4M$58.4M2023+13%2024: $63.7M$63.7M2024+9%2025: $52.0M$52.0M2025−18%
Operating income45673-$270.0M in 2025+215% since 2019
-$300.0M-$200.0M-$100.0M02019: -$85.8M-$85.8M20192020: -$62.8M-$62.8M2020−27%2021: -$78.0M-$78.0M2021+24%2022: -$78.7M-$78.7M2022+1%2023: -$82.4M-$82.4M2023+5%2024: -$171.8M-$171.8M2024+109%2025: -$270.0M-$270.0M2025+57%
Net income45673-$265.9M in 2025+208% since 2019
-$300.0M-$200.0M-$100.0M02019: -$86.4M-$86.4M20192020: -$155.6M-$155.6M2020+80%2021: -$6.6M-$6.6M2021−96%2022: -$71.0M-$71.0M2022+984%2023: -$80.7M-$80.7M2023+14%2024: -$193.5M-$193.5M2024+140%2025: -$265.9M-$265.9M2025+37%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Total revenue, net$52.0M$63.7M$58.4M
Cost of product revenue$6.6M$5.6M$5.3M
Research and development$197.1M$127.6M$61.1M
Selling and marketing$53.9M$41.6M$40.5M
General and administrative$64.4M$60.7M$33.9M
Total costs and operating expenses$322.0M$235.5M$140.8M
Loss from operations-$270.0M-$171.8M-$82.4M
Interest income$18.4M$20.3M$4.0M
Interest expense-$11.8M-$13.6M-$11.3M
Change in fair value of derivative liabilities-$2.5M-$480.0K-$5.2M
Gains and (losses) on extinguishment of debt, net-$27.9M$14.2M
Other gains (expenses)$29.0K-$1.0K
Total other income (expense), net$4.1M-$21.7M$1.6M
Net loss-$265.9M-$193.5M-$80.7M
Net loss per share, basic (in dollars per share)-$1.42-$1.22-$1.01
Weighted average common shares outstanding, basic (in shares)187.2M shares158.3M shares79.8M shares
Net loss per share, diluted (in dollars per share)-$1.42-$1.22-$1.02
Weighted average common shares outstanding, diluted (in shares)187.2M shares158.3M shares85.6M shares

Compare OCULAR THERAPEUTIX, INC with another company

Leadership

Who has led OCULAR THERAPEUTIX, INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Amarpreet Sawhney2014–2017
  2. Antony C. Mattessich2018–2024

Chair

  1. Amarpreet Sawhney2017–2019
  2. Pravin Dugel2024

President

  1. Amarpreet Sawhney2014–2017
  2. Antony C. Mattessich2017–2024

Chief financial officer

  1. George Migausky V.2017
  2. Donald Notman2017–2024

Chief operating officer

  1. James Fortune2014–2017
  2. Patricia Kitchen2021
  3. Donald Notman2026–now
201520202025
Board members and other officers (31)

Former names

  • I-THERAPEUTIX INCMar 6, 2007 to Jul 2, 20092

Timeline

  1. Feb 2, 2018New chief executive Antony C. Mattessich becomes CEO11
  2. Jul 24, 2014New chief executive Amarpreet Sawhney becomes CEO12

Filings

400 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 51 major events, 174 insider forms, 33 large holders, 122 other. The latest 20:

  1. Oct 13, 20264 OWNERSHIP DOCUMENT EDGAR
  2. Oct 8, 2026144 EDGAR
  3. Oct 6, 20264 OWNERSHIP DOCUMENT EDGAR
  4. Oct 6, 20264 OWNERSHIP DOCUMENT EDGAR
  5. Oct 2, 2026144 EDGAR
  6. Oct 2, 2026144 EDGAR
  7. Sep 2, 20264 OWNERSHIP DOCUMENT EDGAR
  8. Aug 31, 2026144 EDGAR
  9. Aug 26, 20264 OWNERSHIP DOCUMENT EDGAR
  10. Aug 26, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Aug 26, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Aug 26, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Aug 24, 2026144 EDGAR
  14. Aug 24, 2026144 EDGAR
  15. Aug 24, 2026144 EDGAR
  16. Aug 24, 2026144 EDGAR
  17. Aug 3, 2026S-8 EDGAR
  18. Aug 3, 202610-Q EDGAR
  19. Aug 3, 20268-K EDGAR
  20. Jul 29, 2026SCHEDULE 13G/A EDGAR

The 400 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 33 such filings since October 2021, the latest 10:

  1. Jul 29, 2026SCHEDULE 13G/A
  2. May 15, 2026SCHEDULE 13G/A
  3. Mar 27, 2026SCHEDULE 13G/A
  4. Feb 17, 2026SCHEDULE 13G/A
  5. Feb 10, 2026SCHEDULE 13G
  6. Feb 10, 2026SCHEDULE 13G/A
  7. Dec 8, 2025SCHEDULE 13G
  8. Nov 14, 2025SCHEDULE 13G/A
  9. Nov 14, 2025SCHEDULE 13G/A
  10. Nov 5, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC32,844,043$322.5M0.0%+190,279
Deep Track Capital, LP19,686,282$193.3M2.8%No change
BlackRock, Inc.19,376,555$190.3M0.0%+3,243,624
Avoro Capital Advisors LLC12,540,000$123.1M1.1%+225,000
Summer Road LLC12,208,296$119.9M74.5%+328,471
Venrock Adviser, LLC10,346,926$101.6M3.1%No change
Vanguard Capital Management LLC8,832,595$86.7M0.0%+113,556
Logos Global Management LP5,300,000$52.0M2.2%+1,450,000
State Street Corp5,233,282$51.4M0.0%+524,863
Geode Capital Management, LLC5,021,092$49.3M0.0%+491,907
Point72 Asset Management, L.P.3,292,193$32.3M0.1%−2,242,792
Dimensional Fund Advisors LP2,783,367$27.3M0.0%+2,133,611
Deltec Asset Management LLC2,476,197$24.3M3.6%+135,577
Balyasny Asset Management L.P.2,270,707$22.3M0.0%−421,915
Octagon Capital Advisors LP2,075,000$20.4M1.9%−1,091,600
Vanguard Portfolio Management LLC1,973,130$19.4M0.0%+378,464
Northern Trust Corp1,799,426$17.7M0.0%+273,800
Goldman Sachs Group Inc1,761,754$17.3M0.0%+651,388
Nuveen, LLC1,697,274$16.7M0.0%+1,286,194
Woodline Partners LP1,667,609$16.4M0.1%No change
TCG Crossover Management, LLC1,647,752$16.2M0.4%No change
UBS Group AG1,551,001$15.2M0.0%+30,370
Adage Capital Partners Gp, L.l.c.1,550,000$15.2M0.0%New
Charles Schwab Investment Management Inc1,533,438$15.1M0.0%+72,261
Defilade Capital Management, L.P.1,490,286$14.6M2.0%+2,641

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49